Frequent nocturnal hemodialysis - A step forward?

JAMA

Volumn 298, Issue 11, 2007, Pages 1331-1333

  Kliger, Alan S ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; PHOSPHATE;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BONE DISEASE; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DEPRESSION; EDITORIAL; GEOGRAPHIC DISTRIBUTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEREDITY; HUMAN; INFLAMMATION; KIDNEY FAILURE; MEDICAL CARE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; NOTE; RENAL REPLACEMENT THERAPY;

CIRCADIAN RHYTHM; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 34548714625     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.11.1331     Document Type: Editorial

References (23)

1. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. http://www.usrds.org/adr_2006.htm. Accessibility verified August 23, 2007.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5)(suppl 3):S112-S119.
3. de Mutsert R, Snijder MB, van der Sman-de Beer F, et al. for the Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol. 2007;18(3):967-974.
4. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004;44(5)(suppl 2):16-21.
5. van Dijk PCW, Zwinderman AH, Dekker FW, et al. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int. 2007;71(1):53-59.
6. McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol. 1998;9(10):1940-1947.
7. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 2000;35(1):80-88.
8. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002;13(4):1061-1066.
9. Eknoyan G, Beck GJ, Cheung AK, et al; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010-2019.
10. Paniagua R, Amato D, Vonesh E, et al; Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307-1320.
11. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S; Mexican Nephrology Collaborative Study Group. Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: the ADEMEX trial. Kidney Int. 2005;67(3):1093-1104.
12. Greene T. What did we learn from the HEMO study? implications of secondary analyses. Contrib Nephrol. 2005;149:69-82.
13. Chan CT, Floras JS, Miller JA, Richardson RMA, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61(6):2235-2239.
14. McPhatter LL, Lockridge RS Jr, Albert J, et al. Nightly home hemodialysis: improvement in nutrition and quality of life. Adv Ren Replace Ther. 1999;6(4):358-365.
15. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005;67(4):1500-1508.
16. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298(11):1291-1299.
17. Chertow GM. "Wishing don't make it so": why we need a randomized clinical trial of high-intensity hemodialysis. J Am Soc Nephrol. 2001;12(12):2850-2853.
18. Kliger AS; for the Frequent Hemodialysis Network Study Group. High-frequency hemodialysis: rationale for randomized clinical trials. Clin J Am Soc Nephrol. 2007;2(2):390-392.
19. Himmelfarb J. Chronic kidney disease and the public health: gaps in evidence from interventional trials. JAMA. 2007;297(23):2630-2633.
20. Zoccali C, Benedetto FA, Mallamaci F, et al; CREED Investigators. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12(12):2768-2774.
21. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759-2767.
22. Gutman RA, Blumenkrantz MJ, Chan YK, et al. Controlled comparison of hemodialysis and peritoneal dialysis: Veterans Administration multicenter study. Kidney Int. 1984;26(4):459-470.
23. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71(4):349-359.